Jeito Capital — Full Portfolio
31 tracked investments · listed companies and verified rows first
Advesya is a clinical-stage biotech company developing cancer and autoimmune disease therapies that target IL-1RAP, an antigen upregulated in various cancers and autoimmune conditions.
BiotechHealthtechMedical DevicesBesançon, FR
Christophe Ferrand(Founder and Board Member (Director of R&D))inMarina Deschamps(Founder (Director of CMC))inAndré Baruchel(Founder and Board Member)in
BoardKsenija Pavletic(A.I. Chief Executive Officer)in
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)
Board seatKsenija Pavletic· per SEC Form D
Quell Therapeutics is a clinical-stage biotech company developing engineered regulatory T cell (Treg) therapies using a patient's own cells to restore immune tolerance.
BiotechDeep TechHealthtech
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Clinical-stage biotech developing anti-CLDN1 ADCs and antibodies for CLDN1+ tumors and fibrotic disease; based in Basel.
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)Ivan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
BiotechCambridge, US
Mohamed Genead(Executive Officer, Director)Michael Tolentino(Executive Officer, Director)David Callanan(Executive Officer)Tarek Hassan(Executive Officer)Derek Kunimoto(Executive Officer)
BoardDavid Guyer(Director)
Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism.
BiotechMedical Devices
Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
France-based preclinical biopharma developing first-in-class therapies for heart failure subpopulations.
Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications.
BiotechHealthtech
Global company developing next-generation eye disease therapies; acquired by Merck & Co.
BiotechHolborn, London
James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)David Robert Guyer(Executive Officer)
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Clinical stage company transforming lives in immune mediated disease
Develops gene therapy treatments for Inherited Retinal Diseases regardless of genetic cause.
SparingVision is a genomic medicine company developing gene therapies for ophthalmic diseases, including SPVN06, a neuroprotective gene therapy for retinal conditions.
BiotechDeep TechDigital Health
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)James Cohen(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.